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This paper summarizes key emerging issues in fragile X-associated tremor/ataxia syndrome (FXTAS) as presented at
the First International Conference on the FMR1 Premutation: Basic Mechanisms & Clinical Involvement in 2013.
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It has been over a decade since the fragile X-associated
tremor/ataxia syndrome (FXTAS) was discovered. The
clinical description of this new condition placed the dis-
order into the family of movement disorders. Movement
disorders are neurological syndromes in which there is
either an excess of movement (referred to as hyperkine-
sias, dyskinesia, or abnormal involuntary movements) or a
paucity of voluntary and automatic movements (hypoki-
nesia). Movement disorders are classified by their motor
phenomenology. While many movement disorders have
predominantly one type of abnormal movement, several
diseases characteristically manifest a combination of
abnormal movements. Because of the variety of motor
phenomenology in FXTAS, patients with this condition
are considered within the combinational movement disor-
ders. In FXTAS, Parkinsonian and cerebellar features were
initially described, but continued research suggests the
disorder also includes non motor features, such as auto-
nomic features, peripheral neuropathy, and neuropsychi-
atric manifestations.
The current definition of FXTAS is that it is caused by
a premutation size expansion (55 to 199 CGG repeats)
in the fragile X mental retardation 1 (FMR1) gene. Full
expansions of more than 200 CGG repeats in FMR1
results in methylation and transcriptional silencing of
the gene. Full mutation carriers have fragile X syndrome,
which is characterized by intellectual disability, seizures,
and autism with onset in childhood.* Correspondence: Deborah_A_Hall@rush.edu
1Department of Neurological Sciences, Rush University, Chicago, IL, USA
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unless otherwise stated.Unlike many other genetic disorders, the genetic ab-
normality that causes FXTAS was described and charac-
terized before the discovery of the movement disorder.
This has enhanced the ability of clinicians who identify
children with fragile X syndrome (FXS) to rapidly iden-
tify parents and grandparents who may have FXTAS. It
has also catalyzed the research in this disease. This paper
is a summary of progress that has been made more recently
in FXTAS and encompasses definitional changes, findings
in women, classification of the cognitive disorders, meas-
urement of clinical features, and report of data from the
first clinical trial in the disorder.Expanding the FXTAS phenotype
The initial description of FXTAS consisted of a neurode-
generative disorder in premutation carriers, mostly in
men over age 50, characterized by intention tremor,
cerebellar gait ataxia, and parkinsonism, as well as brain
atrophy and often middle cerebellar peduncle hyperinten-
sities (the ‘MCP sign’) on magnetic resonance imaging
(MRI) scans [1-4]. Diagnostic criteria [3], as shown in
Table 1, were proposed based on this, with the addition of
the neuropathological hallmark, intranuclear inclusion
bodies [5], soon after. These diagnostic criteria have been
helpful in clinical practice and research to identify affected
persons [6,7].
Since then there has been an enormous amount of
literature suggesting that the disorder has additional
features, as shown in Table 2. Further, some evidence
suggests that REM sleep behavior disorder [8] and small
fiber painful neuropathy [4] also occur in FXTAS. Thus,
the original diagnostic criteria may be inadequate to best
identify affected persons and need to be updated [4,9,10].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Fragile X-associated tremor/ataxia syndrome
FXTAS diagnostic criteria
FXTAS category:a Exam and degree Observation
Definite: Radiological
One clinical major and
one of the following:
Major MRI white matter lesions
in middle cerebellar
peduncle and/or brain
stem
• one radiological
major criterion
Minor MRI white matter lesions
in cerebral white matter
• presence of
intranuclear inclusion
Minor Moderate to severe
generalized atrophy
Clinical
Probable: Major Action tremor
One of the following: Major Cerebellar gait ataxia
Minor Parkinsonism
• two clinical major
criteria
Minor Moderate to severe
short-term memory
deficiency
• one radiological major
criterion and one
clinical minor criterion
Minor Executive function deficit
Pathological
Major Classic FXTAS CNS
intranuclear inclusions
Possible:
Both of the following:
• one clinical major
criterion
• one radiological
minor criterion
aFor all categories, must have FMR1 premutation. CNS, central nervous system;
MRI, magnetic resonance imaging.
Table 2 Revised fragile X-associated tremor/ataxia
syndrome (FXTAS) phenotype
System affected Symptoms and signs Reference
Motor
Action tremor [1,3]
Cerebellar gait ataxia [1,3]
Parkinsonism [1,3]
Reflex myoclonus [11]
Cognitive
Executive dysfunction [12]
Dementia [13]
Autonomic
Urinary dysfunction [3]
Erectile dysfunction [3]
Constipation/fecal
incontinence
[12]
Orthostatic hypotension [14]
Psychiatric
Depression [15-17]
Anxiety [15,17]
Irritability, agitation, apathy [16]
Other CNS, medical
Impaired olfaction [8]
Hearing loss [8]
Hypertension [18,19]
Sleep apnea [20]
Peripheral nervous system
Length dependent neuropathy [3]
Non-length dependent
sensory neuropathy
[4,8,21-28]
Femalesa
Muscle pain/fibromyalgia [19,29]
Hypothyroidism [19]
Radiography
MRI T2 hyperintensities in the
middle cerebellar peduncles
(MCP sign) or brainstem
[4,30]
MRI T2 hyperintensities in the
splenium of the corpus callosum
[31]
MRI white matter lesions in
the cerebrum
[4,30]
Moderate to severe
generalized atrophy
[4,30]
Corpus callosum atrophy [4]
Cerebellar atrophy [4]
aAdditional signs that are typical findings in females, much more so than
males. CNS, central nervous system; MRI, magnetic resonance imaging.
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ated with the FMR1 premutation includes a spectrum of
disorders, depending on stage of life [10]. FXTAS, with
core signs of action tremor and cerebellar gait ataxia, is a
degenerative syndrome that occurs in late life and is the
most severe end of this spectrum.
Several additional clinical features may also occur in
non-FXTAS carriers, do not presage the disease, and are
not specific for FXTAS, such as chronic muscle pain,
hypertension, and anxiety. However, these nonspecific
signs often occur in early stages, and typical signs of
FXTAS may be absent until more advanced stages. Of
note, the expanded FXTAS clinical phenotype includes
women, who tend to present differently than men as
discussed in the next section.
Two major new findings in persons with FXTAS have
been reported. A peripheral neuropathy has been known
to be associated with FXTAS since the first cases. Apartis
et al. [4], found that a non-length dependent neuropathy
is found in 56% of premutation carriers with FXTAS.
Thus, neuropathy is common enough to be a minor clin-
ical diagnostic criterion, but too non-specific and common
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ion. The same group [4] found that MRI T2 hyperintensi-
ties in the splenium of the corpus callosum splenium
(CCS) were as frequent as MCP hyperintensities, and
were useful in identifying patients who had no MCP
sign (Figure 1). Therefore, CCS hyperintensities should be
an additional major MRI criterion for the diagnosis of
FXTAS.
FXTAS was initially described in FMR1 premutation
carriers. Recent reports, however, have shown that individ-
uals carrying a gray zone [32,33] or full mutation without
methylation [34] have developed a classic FXTAS picture,
and thus would meet diagnostic criteria except that they
were not premutation carriers. The pathologic mechanism
that is proposed to underlie FXTAS is FMR1 mRNA
mediated neurotoxicity due to elevated levels of expanded
repeat mRNA in the premutation range. Studies have
shown that increased levels of mRNA levels begin in the
gray zone [35,36]; this likely accounts for FXTAS occur-
ring in individuals with these smaller alleles. Likewise, the
occurrence of FXTAS in association with a full mutation
was seen in a patient with an unmethylated allele [34]; andFigure 1 Corpus callosum abnormalities in fragile X-associated tremo
hyperintensities on axial fluid attenuated inversion recovery (FLAIR) magneFMR1 mRNA is significantly elevated in carriers of
unmethylated full mutation alleles [37]. Given these find-
ings, the diagnostic criteria for FXTAS need to be
amended to allow for the diagnosis in individuals carrying
gray zone or unmethylated full mutation alleles.
The current estimation of the prevalence of the tremor/
ataxia phenotype in premutation carriers older than
50 years is 40% in men and 16% in women, recruited
through families with known fragile X syndrome probands
[19,38,39]. With recognition of the expanded phenotype
and revision of the diagnostic criteria, identification of
FXTAS will be increased. This allows earlier diagnosis and
management of patients and their relatives, and is import-
ant because family members can be educated regarding
their genetic and medical risks.
FXTAS in women
The first carrier women of a FMR1 premutation with
FXTAS were reported in 2004 [6]. More women with
FXTAS have since been described and FXTAS is now
estimated to occur in 8 to 16% of premutation carrier
women older than 50 years [6,19,39]. However, penetrancer/ataxia syndrome (FXTAS). Splenium of the corpus callosum
tic resonance images (a, b and c).
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FXTAS or other premutation problems such as immune
mediated disorders [40,41]. As in men, the penetrance of
FXTAS may increase with age in women, but this is less
well documented [6]. Reduced penetrance in women is
likely due to the protective effect of their normal allele on
the second X-chromosome.
Women with FXTAS may be as severely affected as
males, but in most women symptoms may vary in sev-
eral respects from the original diagnostic criteria [42].
Women with FXTAS tend to have less tremor, ataxia,
white matter disease and brain atrophy on MRI. In only
13% of females affected with FXTAS was the MCP sign
observed [42]. In a small group of women affected with
FXTAS (without a family history of FXS), the MCP sign
was lacking in all patients and hyperintensities in the
pons were less frequently observed [4]. In half of the
women, hyperintensities of CCS were present. Some of
the affected women presented with prominent parkin-
sonism [4].
Less dementia in late stage FXTAS has been reported
in women [13,42], but a recent study suggests that demen-
tia could be more common than initially described [43]. In
this study, neuropathological findings in most premu-
tation carrier women with dementia included cortical
amyloid plaques and neurofibrillary tangles, making
Alzheimer disease (AD) a possible cause of their demen-
tia. The authors suggested that a synergistic effect could
cause the disease progression in some FXTAS cases.
In contrast to premutation carrier men, medical co-
morbidities are more common in women both with and
without FXTAS. A higher incidence of hypothyroidism
and fibromyalgia is reported in women with FXTAS than
in men with FXTAS and age-matched controls [24,35].
Peripheral neuropathy, seizures and hypertension are
also reported to be present more often in females with
FXTAS than in controls [18,19]. Presence of FXTAS
and other (neurological) disorders such as multiple
sclerosis have been described in some carrier women
[44,45]. Interestingly, although approximately 20% of
carrier women have primary ovarian failure [46], one
study reports that it is not associated with later onset
of FXTAS [19].
Emerging issues in clinical classification of
cognitive disorders in FXTAS
Over 50% of patients with FXTAS show cognitive and
behavioral changes, including impairment in executive
function, processing speed and mood dysregulation,
and increased risk for mood and anxiety disorders
[8,13,15,16,31,47-49]. Additional features of apathy,
disinhibition, and impairments in behavioral regulation
suggest widespread dysfunction of the prefrontal lobe and
its connections [12,16,50]. Collectively these features areconsistent with the fronto-subcortical involvement that is
commonly seen in association with other movement dis-
orders including Parkinson disease (PD) and progressive
supranuclear palsy [13,16].
Retrospective reports suggest that cognitive dysfunc-
tion emerges later than tremor and ataxia, [8,13] but
many experience memory and executive dysfunction
earlier than tremor or ataxia [50]. Cognitive dysfunction
may be partly determined by disease duration or age.
However, there is also evidence that cognitive dysfunction
may be moderated by the FMR1 gene. Larger CGG repeat
expansions have been associated with increased relative
risk for cognitive impairment [51] and specific impair-
ments on measures of general intelligence [12,52,53],
response inhibition and verbal fluency [54,55]. More-
over, volume loss and reduced activation in brain
regions associated with working memory have been
linked to larger CGG repeats and increased FMR1 mRNA
respectively [48,56].
The classification of the cognitive disorder associated
with FXTAS has important research and clinical im-
plications. A threshold for determining the presence of
a cognitive disorder associated with FXTAS has not
been established. The fifth edition of the Diagnostic
and Statistical Manual (DSM-5) [57] introduces a new
framework for classifying Mild or Major Neurocognitive
Disorder (NCD) due to a variety of etiologies. This
can be adopted for use in FXTAS. Cognitive impair-
ment can be described as fulfilling criteria for Mild
or Major NCD due to FXTAS, depending on the im-
pact of cognitive symptoms on activities of daily living.
Unlike its predecessor, DSM-5 does not require impair-
ment in memory for a diagnosis of Mild or Major NCD,
making the criteria more suitable for fronto-subcortical
syndromes such as FXTAS.
The clinical classification of cognitive disorders in
FXTAS can be challenging, especially in the elderly
where multiple pathologies are more likely to co-exist. A
number of post-mortem case studies examining brain
tissue from patients with FXTAS have revealed evidence
of co-morbid pathologies including multiple sclerosis,
AD and dementia with Lewy bodies [44,45,58] in addition
to FXTAS inclusions. Atypical cognitive phenotypes or
atypical progression of symptoms may suggest the pres-
ence of co-morbid neurodegenerative conditions. Con-
sideration of co-morbid degenerative syndromes has
implications for clinical course and treatment. As postural
instability and gait disturbance are associated with in-
creased rates of cognitive decline in other motor disorders
(for example, PD [59]), ataxia should be further evaluated
as a possible association with cognitive decline in FXTAS.
In fact, a study of 50 men with FXTAS suggested that cog-
nitive impairment was positively associated with longer
duration of ataxia [8].
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The FXTAS Rating Scale was created to capture the
motor abnormalities, specifically tremor, ataxia and par-
kinsonism, in patients with FXTAS [52]. The scale was
composed of items from the Clinical Rating Scale for
Tremor [60], the International Cooperative Ataxia Rating
Scale [61] and the Unified Parkinson’s Disease Rating
Scale [62] with a tandem gait test added. The scale is
designed to be administered by a neurologist trained to
use the scale on either a live patient or a videotape of a
patient, which captures the items to be rated. The items
are all rated from a neurological exam and there is no
patient-report or historical items. Clinimetric qualities of
the scale have been evaluated by using scores from move-
ment disorder neurologists blinded to gene status rating
videotapes of premutation carriers using a structured
videotape protocol. Four hundred and twenty-one indi-
vidual ratings represented the gamut of FXTAS severity.
Internal consistency, or the general agreement between
items and the total score of the FXTAS Rating Scale was
acceptable (Cronbach’s alpha = 0.93). However, some
items had a less than ideal item to total score correlation,
suggesting limited utility of these items for assessing
overall FXTAS severity. The structure of the scale,
when examined using exploratory factor analysis, encom-
passes ten domains or factors. These ten factors included
measures of bradykinesia, ataxic signs, action tremor,
rigidity, dysarthria, upper limb dystonia, rest tremor, lower
limb dystonia, abnormal eye signs, and head tremor with
dystonic voice. Although these ten factors were identified,
many of the individual items were associated with mul-
tiple factors, suggesting a lack of domain specificity for
those items. To determine the responsivity of the scale,
retrospectively collected FXTAS Rating Scale scores of
premutation carriers between 2001 and 2012 were uti-
lized. Mean follow up time of the subjects (n = 67) was
38.5 months and mean change in score from baseline to
follow up was +4.32 points (SD = 13.46). This was calcu-
lated to be an average yearly change of +2.55 points (95%
CI was −12.44 to +17.53). The studies show that FXTAS
Rating Scale has good internal consistency, but specific
items need to be altered or eliminated to complete devel-
opment of the scale.
Falls and balance issues are clearly a major aspect of
FXTAS and the FXTAS Motor Rating Scale may not be
sensitive enough to detect early balance dysfunction in
the disease. Highly sensitive early markers of disease onset
are critically needed to characterize the subtle balance
deficits that may not be identifiable on the neurological
exam in early FXTAS or in premutation carriers without
FXTAS. Computerized Dynamic Posturography (CDP) with
a Neurocom® Balance Master has been used in a small
series of premutation carriers with and without a definitive
diagnosis of FXTAS [63] to investigate balance in thispopulation compared with normative data from a group of
healthy controls provided by the Neurocom® manufacturer.
CDP testing, in premutation carriers over age sixty
(n = 8 between 60 and 69 years of age and n = 6 greater
than 70 years of age), demonstrated abnormally low scores
on conditions of the Sensory Organization Test (SOT)
that reflect vestibular system balance deficits (See Figure 2;
P = 0.02 to < 0.001). In the SOT, the relative somatosen-
sory, visual and vestibular contributions to balance control
are tested by evaluating balance in six different conditions
in which somatosensory and/or visual inputs in various
combinations are eliminated or made unreliable for main-
tenance of balance. On the CDP motor control test, which
measures latency of automatic postural responses to bal-
ance disruption, response latencies to medium and large
forward and backward translations were significantly lon-
ger in older premutation carriers (0.002 > P < 0.0001). The
CDP limits of stability test, which measures maximum
distance one can displace their center of gravity without
stepping or falling, showed significantly reduction for
maximum excursion to targets and directional control
while moving toward a target, in the premutation carrier
group at all ages tested (0.05 ≥ P < 0.0001). Scores on ves-
tibular conditions of the SOT were reduced not only in
carriers with evidence of FXTAS on exam and on the
FXTAS Rating Scale, but also in a subset of carriers with
normal neurological exams and normal scores on the
FXTAS Rating Scale. A ‘Balance subscale’ score of the
FXTAS Rating Scale scores correlated with severity of the
deficit on vestibular SOT conditions (r = 0.56; P = 0.02).
These analyses suggest that CDP may be a more sensitive
balance ‘marker’ than the FXTAS Rating Scale in detecting
preclinical disease and for risk prediction. Larger longitu-
dinal studies are needed to fully validate and develop this
and other such measures.
Memantine for FXTAS
Memantine, an antagonist of N-methyl-D-aspartate
(NMDA) glutamate receptor approved for the treatment
of moderate to severe AD, has been suggested to be of
therapeutic benefit in a number of neurological disorders
associated with over-activation of glutamate receptors,
including AD, PD, and Huntington’s disease [64]. Anec-
dotal reports have suggested that memantine could be
helpful in the treatment of FXTAS [65]. There is evidence
of down-regulation of GABA pathways causing [66] exces-
sive glutamate to remain at the synapse leading to possible
glutamate toxicity [24]. Based on this mechanism, a ran-
domized, double-blind, placebo-controlled trial of mem-
antine in individuals with FXTAS ages 34 to 80 years was
carried out [25]. Ninety-four participants were random-
ized to either memantine or placebo and were treated for
one year. There was no improvement over placebo in the
primary outcome measures of intention tremor severity as
Figure 2 Computed dynamic posturography in fragile X-associated tremor/ataxia syndrome (FXTAS). (a and b) Neurocom®
Computerized Dynamic Posturography (CDP) Equilibrium scores on all six conditions of the Sensory Organization Test (SOT) and the SOT
composite (COMP) score between FMR1 premutation carriers and controls in the 60 to 69 year and the≥ 70 year-old age group. Data is
expressed as mean ± SEM. Lower SOT scores signify greater postural sway. Worse performance on conditions 5 and 6 of the SOT reflect the
inability to appropriately use vestibular information for the control of balance.
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1.01 ± 0.75 versus 1.76 ± 2.13, P = 0.0785) or executive
function as measured by the Behavior Dyscontrol Scale
(16.12 ± 5.43 versus 15.72 ± 3.93, P= 0.7268) in an intention-
to-treat analysis. More mild adverse events (AEs) were
observed in the placebo group and more moderate AEs
occurred in the memantine group (P = 0.007). This
study suggests that memantine is not helpful for the
primary problems of FXTAS, specifically tremor and ex-
ecutive function.A sub-study using event related potentials (ERP) in a
word repetition paradigm was performed in order to
elicit N400 repetition effects with congruous and incon-
gruous words. There were 21 patients in the memantine
group and 20 in the placebo group who underwent
successful ERP studies before and after one year of
treatment. The memantine group exhibited larger im-
provements on the cued recall test for targeted words
compared to the placebo group (P = 0.050). The placebo
group displayed statistically significant reduction of the
Table 3 Revised fragile X-associated tremor/ataxia syndrome (FXTAS) diagnostic criteria
FXTAS category:a Exam and degree Observation
Definite: Radiological
One clinical major and one of the following: Major MRI white matter lesions in middle cerebellar peduncle
• one radiological major criterion Major MRI white matter lesions in splenium of the corpus callosum
• presence of intranuclear inclusion Minor MRI white matter lesions in cerebral white matter
Minor Moderate to severe generalized atrophy
Clinical
Probable: Major Action tremor
One of the following: Major Cerebellar gait ataxia
• two clinical major criteria Minor Parkinsonism
• one radiological major criterion and one clinical minor criterion Minor Moderate to severe short-term memory deficiency
Minor Executive function deficit
Minor Neuropathy
Pathological
Major Classic FXTAS CNS intranuclear inclusions
Possible:
Both of the following:
• one clinical major criterion
• one radiological minor criterion
aFor all categories, must have FMR1 gray zone, premutation or full mutation.
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group showed preservation of the N400 repetition effect,
with a significant trend for larger N400 repetition effect
amplitude after one year of treatment with memantine
[26]. Correlational tests revealed that increased N400
repetition effect amplitudes were associated with im-
proved cued-recall scores for the congruous target words
(one year to baseline) across all subjects (r = 0.36, P =
0.02), and in the memantine group (r = 0.46, P = 0.038),
but not within the placebo group (r = 0.17, P = 0.46). This
sub-study suggests that the ERP paradigm may be a sensi-
tive measure to document some limited benefit from
memantine in individuals with FXTAS.
Future directions
While the prevalence of the FXTAS is estimated to be
similar to that of other neurodegenerative disorders [27],
FXTAS is under-recognized and frequently misdiagnosed
[28]. While neurologists are becoming more aware of
FXTAS, approximately half of affected persons are seen
and managed by primary care physicians [28]. Improved
education of physicians and more accurate, broader
diagnostic criteria, as in Table 3, would improve diagnosis.
Health care professionals especially need to be educated
about the expanded female phenotype, as these carriers
have serious genetic and medical risks. Keeping in mind
that a family history should be checked, but also that the
family history may be negative for clear FMR1 related
disorders, health care professionals should consider genetesting if a patient over age 50 has unexplained cerebellar
gait ataxia, unexplained action tremor and dementia, or
the MCP or CCS hyperintensity on MRI and some FXTAS
signs, as in Table 2.
Many important avenues of research need attention.
The female FXTAS phenotype requires further study to
accurately define medical risks, especially regarding
endocrine dysfunction and chronic pain. Genetic, epigen-
etic and environmental factors that predispose carriers to
develop FXTAS need identification. Further, to date only
one randomized, controlled trial to study modification of
progression of FXTAS has been conducted. The tools for
these studies, for example, the FXTAS Rating Scale and
other motor measures such as the Neurocom®, need re-
finement, and the molecular science behind such trials
needs to be established.
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